Literature DB >> 29068155

Longitudinal assessment of T cell inhibitory receptors in liver transplant recipients and their association with posttransplant infections.

Krupa R Mysore1,2, Rafik M Ghobrial2,3, Sunil Kannanganat2, Laurie J Minze2, Edward A Graviss4, Duc T Nguyen4, Katherine K Perez5, Xian C Li2,3.   

Abstract

Current immunosuppression regimens in organ transplantation primarily inhibit T cells. However, T cells are also critical in protective immunity, especially in immune-compromised patients. In this study, we examined the association of T cell dysfunction, as marked by expression of T cell exhaustion molecules, and posttransplant infections in a cohort of liver transplant patients. We focused on Programmed Death 1 (PD-1) and T cell Ig- and mucin-domain molecule 3 (Tim-3), which are potent co-inhibitory receptors, and their persistent expression often leads to T cell dysfunction and compromised protective immunity. We found that patients with the highest expression of PD-1 +Tim-3+ T cells in the memory compartment before transplantation had increased incidence of infections after liver transplantation, especially within the first 90 days. Longitudinal analysis in the first year showed a strong association between variability of PD-1 and Tim-3 expression by T cells and infectious episodes in transplant patients. Furthermore, T cells that expressed PD-1 and Tim-3 had a significantly reduced capacity in producing interferon (IFN)-γ in vitro, and this reduced IFN-γ production could be partially reversed by blocking PD-1 and Tim-3. Interestingly, the percentage of Foxp3+ regulatory T cells in liver transplant patients was stable in the study period. We concluded that the functional status of T cells before and after liver transplantation, as shown by PD-1 and Tim-3 expression, may be valuable in prognosis and management of posttransplant infections.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  T cell biology; cell death: exhaustion; costimulation; immunobiology; infectious disease; liver disease: infectious; liver transplantation/hepatology; translational research/science

Mesh:

Substances:

Year:  2017        PMID: 29068155      PMCID: PMC5790618          DOI: 10.1111/ajt.14546

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  48 in total

1.  Infections in liver transplant recipients.

Authors:  Fabian A Romero; Raymund R Razonable
Journal:  World J Hepatol       Date:  2011-04-27

2.  OPTN/SRTR 2013 Annual Data Report: liver.

Authors:  W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2015-01       Impact factor: 8.086

Review 3.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

Review 4.  T cell exhaustion during persistent viral infections.

Authors:  Shannon M Kahan; E John Wherry; Allan J Zajac
Journal:  Virology       Date:  2015-01-22       Impact factor: 3.616

5.  Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration.

Authors:  M Shodell; K Shah; F P Siegal
Journal:  Lupus       Date:  2003       Impact factor: 2.911

Review 6.  Emerging Tim-3 functions in antimicrobial and tumor immunity.

Authors:  Kaori Sakuishi; Pushpa Jayaraman; Samuel M Behar; Ana C Anderson; Vijay K Kuchroo
Journal:  Trends Immunol       Date:  2011-06-21       Impact factor: 16.687

7.  Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes.

Authors:  Olivier Joffre; Thibault Santolaria; Denis Calise; Talal Al Saati; Denis Hudrisier; Paola Romagnoli; Joost P M van Meerwijk
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

8.  Viral immune evasion due to persistence of activated T cells without effector function.

Authors:  A J Zajac; J N Blattman; K Murali-Krishna; D J Sourdive; M Suresh; J D Altman; R Ahmed
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

9.  Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation.

Authors:  Niloufar Safinia; Trishan Vaikunthanathan; Henrieta Fraser; Sarah Thirkell; Katie Lowe; Laura Blackmore; Gavin Whitehouse; Marc Martinez-Llordella; Wayel Jassem; Alberto Sanchez-Fueyo; Robert I Lechler; Giovanna Lombardi
Journal:  Oncotarget       Date:  2016-02-16

Review 10.  Regulatory T Cells in Hepatitis B and C Virus Infections.

Authors:  Min Kyung Jung; Eui-Cheol Shin
Journal:  Immune Netw       Date:  2016-12-22       Impact factor: 6.303

View more
  5 in total

1.  Expansion of Double-Negative T Cells in Patients before Liver Transplantation Correlates with Post-Transplant Infections.

Authors:  Hong Lei; Min Tian; Xiaogang Zhang; Xuemin Liu; Bo Wang; Rongqian Wu; Yi Lv
Journal:  J Clin Med       Date:  2022-06-17       Impact factor: 4.964

2.  Tacrolimus and Sirolimus Once Daily Monotherapy Regimen as a Safe and Effective Long-Term Maintenance Immunosuppressive Therapy in Pediatric Liver Transplantation.

Authors:  S M Dehghani; I Shahramian; M Ataollahi; A Baz; H Foruzan; S Gholami; M Goli
Journal:  Int J Organ Transplant Med       Date:  2020

3.  Risk factors for extrapulmonary dissemination of tuberculosis and associated mortality during treatment for extrapulmonary tuberculosis.

Authors:  Xu Qian; Duc T Nguyen; Jianxin Lyu; Andreas E Albers; Xiaohong Bi; Edward A Graviss
Journal:  Emerg Microbes Infect       Date:  2018-06-06       Impact factor: 7.163

Review 4.  Influence of T Cell Coinhibitory Molecules on CD8+ Recall Responses.

Authors:  Anna B Morris; Layne E Adams; Mandy L Ford
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

Review 5.  Clinical and biomarker assessment of frailty in liver transplantation.

Authors:  Tumininu Ayorinde; Guergana Panayotova; Aanchal Sharma; Keri E Lunsford
Journal:  Curr Opin Organ Transplant       Date:  2021-10-01       Impact factor: 2.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.